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Screening and
Toxigenic
Corynebacteria
Spread
To the Editor: Diphtheria is rare
in countries with high vaccination
coverage, but as seen in Europe in
recent decades, control can disinte-
grate rapidly. When diphtheria is rare,
surveillance is challenging because
clinicians have no experience with the
infection, and disease may be mild or
atypical in vaccinated persons (1).
Clinicians may give inadequate infor-
mation to laboratories, and appropri-
ate investigations may not be per-
formed. Identifying cases is facilitated
if all throat swabs from patients with
pharyngitis are screened by laborato-
ries for corynebacteria, but this proce-
dure is expensive and time consum-
ing. To help balance priorities in diph-
theria surveillance, we evaluated the
potential benefits of microbiologic
screening in preventing secondary
spread of toxigenic corynebacteria in
England and Wales and estimated the
possible consequences of not detect-
ing a case.
The mean number of secondary
cases that might occur per index case
if screening is not undertaken
depends on the mean number of con-
tacts and attack rates, vaccine cover-
age and efficacy, and duration of pro-
tection. Some of these factors are not
known precisely, so we estimated
them within plausible ranges of val-
ues. We varied the number of contacts
per case-patient from 2 to 20.
Secondary attack rates in susceptible
persons are difficult to estimate and
distinguish from carriage rates (2),
and we varied these from 5% to 50%.
Vaccine efficacy in children was var-
ied from 50% to 95%. We estimated
the susceptibility of UK adults at
40% (3), vaccination coverage in
children at 95% (4), and case-fatality
ratio at 6% to 10% (5). For simplici-
ty, the ratio of adults to children
among contacts was assumed to be
1:1. We assumed that without specif-
ic microbiologic identification of
cases, no intervention would take
place and that intervention to protect
contacts is 100% effective. Such
intervention includes early treatment
and isolation of cases, chemoprophy-
laxis, and booster vaccination of con-
tacts. The number of cases that need
to be detected to prevent 1 secondary
case for different numbers of contacts
and attack rates was calculated as the
inverse of the number of secondary
cases that would result from each
case not detected by screening.
The number of cases that must be
detected by microbiologic screening
to prevent 1 secondary case was most
affected by varying the number of
contacts per patient and the secondary
attack rate (Figure). If one assumes
vaccine efficacy of 95%, an attack
rate in susceptible contacts of 5%, and
4 contacts per patient, 1 secondary
case is prevented for every 18 cases
detected; if attack rates are 30%, then
1 secondary case is prevented for <5
index cases detected. If vaccine effi-
cacy was 50%, the number of cases
that would need to be detected to pre-
vent 1 secondary case would fall from
18 to <10 cases for a mean of 4 con-
tacts per case and secondary attack
rates of 5%.
For the 53 toxigenic strains of
corynebacteria detected in England
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Figure. Number of cases needed to detect to prevent 1 secondary case.LETTERS
and Wales from 1993 to 2000, an
estimated 2–10 secondary cases
would have been prevented if attack
rates were 5% and each patient had 4
contacts. The number of index cases
needed to be detected to prevent 1
death (assuming 6%–10% case-fatali-
ty ratio) would have been 150–180
with attack rates of 5% and 50–83
with attack rates of 30%. Thus, deaths
were not likely to have been prevent-
ed during this period by screening.
Are the parameter estimates valid?
We focused on secondary cases, but
spread in outbreaks may be exponen-
tial, so the effect of missing cases may
be greater once tertiary cases and fur-
ther spread are taken into account.
Vaccination coverage may be higher
or lower in different risk groups.
Secondary attack rates in the literature
are reported from outbreaks and
regions with vulnerable populations
during periods of high incidence and
may not apply in affluent countries
with high coverage and may be <5%.
Adult protection may be better than
indicated by serosurveys and may
have improved in the United
Kingdom with use since 1994 of com-
bined tetanus-diphtheria toxoid vac-
cine instead of tetanus toxoid for
injuries (5). 
Outbreaks are not reported from
countries without routine screening
(1), which indicates that some of our
assumptions and estimates may be
incorrect. Alternatively, this fact may
indicate defective surveillance; coun-
tries that do not detect primary cases
may not detect secondary cases. 
Surveillance for diphtheria in
European Union member states varies
widely (1). Only 5 of 19 reporting
countries screen throat swabs routine-
ly for corynebacteria, raising doubts
about the quality of surveillance. The
absence of reports of diphtheria may
not reflect the absence of disease or of
circulating toxigenic corynebacteria.
Our results show the possible conse-
quences of not detecting such infec-
tions and help demonstrate the public
health priority of diphtheria surveil-
lance.
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Rickettsia slovaca
Infection, France 
To the Editor: Rickettsia slovaca
was first isolated in 1968 in a
Dermacentor marginatus tick collect-
ed in Slovakia, and serologic evidence
of infection with this bacteria was
reported in patients with enlarged
lymph nodes and a scalp eschar after
being bitten by a tick (1). However,
the first proven case of R.  slovaca
infection was reported only in 1997 in
France (2). This rickettsiosis is called
tickborne lymphadenopathy (TIBO-
LA) because the most pronounced
sign is lymph node enlargement. In
Spain the same condition is called
Dermacentor-borne-necrosis-erythe-
ma lymphadenopathy (3,4).
In this study, we describe 14 new
patients with TIBOLA from southern
France who sought treatment from
January 2004 to May 2005 and com-
pare the features of these patients with
those in whom Mediterranean spotted
fever (MSF) was diagnosed during
the same period. All the patients were
referred to our center with a suspected
rickettsial infection characterized by a
tick bite located on the scalp, an inoc-
ulation eschar, and enlarged lymph
nodes (see online Appendix Figure,
available at http://www.cdc.gov/nci-
dod/EID/vol12no03/05-0911-appG
.htm). For each patient, an acute-
phase and a convalescent-phase
serum sample were obtained for sero-
logic analysis. Culture and poly-
merase chain reaction (PCR) were
performed on tick, skin biopsy, or
blood specimens. A multiple-antigen
immunofluorescence assay (IFA) was
performed by using 5 spotted fever
group (SFG) rickettsial antigens: R.
conorii conorii, R. slovaca, R. helveti-
ca,  R.  sibirica mongolitimonae, and
R. felis. Titers of at least 64 for
immunoglobulin G (IgG) and 32 for
IgM in acute-phase serum samples,
evidence of seroconversion with 4-
fold increases in IgG titers, or both,
were considered as evidence of recent
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 3, March 2006 521